BridgeBio Pharma (BBIO) Revenue & Revenue Breakdown
BridgeBio Pharma Revenue Highlights
Latest Revenue (Y)
$9.30M
Latest Revenue (Q)
$2.17M
Main Segment (Y)
License
Main Geography (Y)
License
BridgeBio Pharma Revenue by Period
BridgeBio Pharma Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $9.30M | -88.02% |
2022-12-31 | $77.65M | 11.38% |
2021-12-31 | $69.72M | 745.14% |
2020-12-31 | $8.25M | -79.66% |
2019-12-31 | $40.56M | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | - |
BridgeBio Pharma Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $2.17M | -98.97% |
2024-03-31 | $211.12M | 11998.57% |
2023-12-31 | $1.75M | -57.35% |
2023-09-30 | $4.09M | 149.30% |
2023-06-30 | $1.64M | -10.13% |
2023-03-31 | $1.83M | -2.35% |
2022-12-31 | $1.87M | 453.25% |
2022-09-30 | $338.00K | -99.54% |
2022-06-30 | $73.75M | 4253.36% |
2022-03-31 | $1.69M | -86.85% |
2021-12-31 | $12.89M | 449.74% |
2021-09-30 | $2.34M | -95.66% |
2021-06-30 | $54.02M | 11593.51% |
2021-03-31 | $462.00K | 278.69% |
2020-12-31 | $122.00K | -98.50% |
2020-09-30 | $8.13M | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | -100.00% |
2019-12-31 | $13.82M | -48.32% |
2019-09-30 | $26.74M | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | - |
BridgeBio Pharma Revenue Breakdown
BridgeBio Pharma Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 20 | Dec 19 |
---|---|---|
License | $8.00M | $13.80M |
Latest
Quarterly Revenue by Product
Product/Service | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
---|---|---|---|---|---|---|---|
License and Service | $1.83M | $338.00K | $73.75M | - | - | - | - |
Product | - | - | - | $1.46M | $759.00K | $987.00K | - |
License | - | - | - | $235.00K | $1.58M | $8.00M | - |
Latest
BridgeBio Pharma Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 19 |
---|---|
License | $13.80M |
Latest
Quarterly Revenue by Country
Country | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Sep 20 |
---|---|---|---|---|---|---|---|
License and Service | $1.83M | $338.00K | $73.75M | - | - | - | - |
Product | - | - | - | $1.46M | $759.00K | $987.00K | - |
License | - | - | - | $235.00K | $1.58M | $8.00M | - |
Latest
BridgeBio Pharma Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
PTCT | PTC Therapeutics | $937.82M | $135.42M |
AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
BPMC | Blueprint Medicines | $249.38M | $128.18M |
KRYS | Krystal Biotech | $50.70M | $83.84M |
BBIO | BridgeBio Pharma | $9.30M | $2.17M |
XFOR | X4 Pharmaceuticals | - | $560.00K |
DAWN | Day One Biopharmaceuticals | - | $20.07M |
ABOS | Acumen Pharmaceuticals | - | - |
INZY | Inozyme Pharma | - | - |
MDGL | Madrigal Pharmaceuticals | - | $62.17M |
TERN | Terns Pharmaceuticals | - | - |